Eylea™ 8mg Expands Again — Now Approved for Retinal Vein Occlusion in UK and Korea

On February 25, 2026, Bayer announced that Eylea™ 8mg — the high-dose version of its blockbuster eye drug — received approval in the UK for treating macular edema following retinal vein occlusion (RVO).

Just two days later, Korea followed suit — approving the same indication, along with a major dosing upgrade: patients can now go up to 24 weeks between injections, down from a previous minimum of 8 weeks.

This is the third approved indication for Eylea™ 8mg in both countries — joining wet AMD and diabetic macular edema (DME).

For patients suffering from RVO — a condition that can cause sudden, severe vision loss — this approval offers not just a new treatment, but fewer injections, less disruption, and better long-term outcomes.

Why This Approval Is a Big Deal for Eye Care

RVO — which includes branch, central, and hemiretinal vein occlusion — affects millions worldwide. It’s the second most common retinal vascular disease after diabetic retinopathy.

Until now, treatment options were limited — often requiring frequent injections and offering inconsistent results.

Eylea™ 8mg changes that.

By extending the dosing interval to 24 weeks, it reduces the burden on patients and clinics — especially important in regions with limited access to ophthalmologists.

And because it’s already approved for wet AMD and DME, this expansion solidifies Eylea™ 8mg as a versatile, long-acting workhorse in retinal care — not just a niche drug.

The Global Approval Map — And What’s Next

This isn’t happening in isolation.

• FDA approved Eylea™ 8mg for RVO in November 2025
• European Commission followed in January 2026
• Japan and Australia already approved it for wet AMD and DME
• Marketing applications are pending in Japan for RVO (submitted May 2025)

Bayer and Regeneron — who co-developed the drug — are playing a global game: aligning approvals, optimizing dosing, and expanding access.

And they’re not stopping here. With more indications likely in the pipeline, Eylea™ 8mg is on track to become the standard of care for multiple retinal diseases — not just one.

Biosimilars Are Already in the Ring — And They’re Getting Closer

While innovators expand, biosimilar developers are racing to catch up.

Alvotech is developing AVT29, a biosimilar to Eylea™ 8mg. In June 2024, they partnered with Advanz Pharma for commercialization in Europe — and Teva holds U.S. rights.

Meanwhile, biosimilars of the 2mg version (Eylea®) are already on the market:

• Mynzepli® (Alvotech) — UK, Canada, Japan
• Pavblu® (Amgen) — U.S.
• Afqlir®/Enzeevu® (Sandoz) — UK, Australia, Canada
• Afilivu®/Opuviz® (Samsung Bioepis) — Korea
• Eydenzelt® (Celltrion) — UK, Europe

This means that as Eylea™ 8mg grows, so will the pressure from biosimilars — especially in markets where cost and access are critical.

The Bottom Line: Fewer Injections, More Competition, Better Care

This approval isn’t just about adding another label.

It’s about:

• Improving patient quality of life — fewer clinic visits, longer intervals
• Expanding global access — especially in regions where frequent injections aren’t feasible
• Accelerating biosimilar competition — which will drive down costs and increase availability

For ophthalmologists, it’s a win.
For patients, it’s relief.
For the biologics market? It’s a reminder that innovation doesn’t stop at approval — it evolves with every new indication, every new dosing schedule, every new competitor.

Because in 2026, the future of eye care isn’t just about seeing clearly — it’s about living more freely.